MENU
BMED
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

BMED stock forecast, quote, news & analysis

The investment seeks to maximize total return... Show more

Category: #Health
Interact to see
Advertisement
A.I.Advisor
published price charts
BMED
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for BMED with price predictions
Nov 02, 2026

Momentum Indicator for BMED turns positive, indicating new upward trend

BMED saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 77 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for BMED just turned positive on October 15, 2026. Looking at past instances where BMED's MACD turned positive, the stock continued to rise in 34 of 44 cases over the following month. The odds of a continued upward trend are 77%.

Following a +3.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where BMED advanced for three days, in 223 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

The Aroon Indicator entered an Uptrend today. In 217 of 281 cases where BMED Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.

Bearish Trend Analysis

The 10-day RSI Indicator for BMED moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In 21 of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at 60%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMED declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

BMED broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Abbott Laboratories (NYSE:ABT), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Moderna (NASDAQ:MRNA), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The investment seeks to maximize total return. Under normal market conditions, the fund will invest at least 80% of its net assets plus any borrowings for investment purposes in equity securities of companies principally engaged in the health sciences group of industries. While the fund will invest primarily in companies providing products and services for human health, it may also invest in companies whose products or services relate to the growth or survival of animals and plants.

Market Cap

The average market capitalization across the iShares Health Innovation Active ETF (BMED) ETF is 49.05B. The market cap for tickers in the group ranges from 307.66M to 658.38B. JNJ holds the highest valuation in this group at 658.38B. The lowest valued company is EIKN at 307.66M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Health Innovation Active ETF (BMED) ETF was 2%. For the same ETF, the average monthly price growth was 7%, and the average quarterly price growth was 28%. GMAB experienced the highest price growth at 23%, while ILMN experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the iShares Health Innovation Active ETF (BMED) ETF was 32%. For the same stocks of the ETF, the average monthly volume growth was 14% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 44
Price Growth Rating: 46
SMR Rating: 78
Profit Risk Rating: 76
Seasonality Score: 22 (-100 ... +100)
Momentum Indicator for BMED turns positive, indicating new upward trend